First-line anti-EGFR agents (panitumumab or cetuximab) plus chemotherapy in patients with metastatic colorectal cancer: Onco-colon Turkey study subgroup analysis

Isikdogan, A.Turk, H.Bilir, C.Sendur, M.Karabulut, B.Artac, M.Cicin, I.2024-08-042024-08-0420220923-75341569-8041https://doi.org/10.1016/j.annonc.2022.04.180https://hdl.handle.net/11616/103218ESMO 24th World Congress on Gastrointestinal Cancer -- JUN 29-JUL 02, 2022 -- Barcelona, SPAIN[Abstract Not Available]eninfo:eu-repo/semantics/openAccess[No Keywords]First-line anti-EGFR agents (panitumumab or cetuximab) plus chemotherapy in patients with metastatic colorectal cancer: Onco-colon Turkey study subgroup analysisConference Object33S281S28110.1016/j.annonc.2022.04.180WOS:000823826500103Q1